Inhibitors of raf kinases
AssigneeKinnate Biopharma Inc.
InventorsStephen W. KALDOR, Toufike KANOUNI, Lee ARNOLD
Life of this patent
Estimating the term…
Abstract
Provided herein are heteroaryl inhibitors of receptor tyrosine kinase effector (RAF), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of disease.
Claims31
-104. (canceled)
A compound, or pharmaceutically acceptable salt or solvate thereof, having the structure of Formula (I):
- wherein,
- V is hydrogen, halogen, —CN, optionally substituted C1-C4 alkyl, —CD3, optionally substituted C1-C4 alkoxy, optionally substituted C1-C4 alkenyl, or optionally substituted C1-C4 alkynyl;
- U is selected from optionally substituted alkyl, —CD3, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl group, optionally substituted —COalkyl, optionally substituted —COcycloalkyl;
- X is C—H, C-D, or C—F;
- R2 is H, D or F;
- R4 is halogen, optionally substituted C1-C3 alkyl, —CD3, or optionally substituted C1-C3 alkoxy;
- R6 is H, D, Cl or F;
- and
- Z is an optionally substituted nitrogen-containing heteroaryl group.
(canceled)
The compound of claim 1, or pharmaceutically acceptable salt or solvate thereof, wherein the optionally substituted nitrogen-containing heteroaryl group is substituted with a halogen, or an optionally substituted C1-C4 alkyl.
The compound of claim 1, or pharmaceutically acceptable salt or solvate thereof, wherein V is Me, U is optionally substituted alkyl, and Z is a 6-membered optionally substituted monocyclic nitrogen-containing heteroaryl group.
Dependencies are inferred from the claim text.